Trials / Completed
CompletedNCT03321695
A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina
An Observational Study of the Safety of Atezolizumab in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 44 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a study of the safety and effectiveness of atezolizumab in participants with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Participants also will have progressed on an appropriate approved targeted therapy if their tumor has epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) gene abnormalities treated in common clinical practice settings in Argentina.
Conditions
Timeline
- Start date
- 2017-12-27
- Primary completion
- 2019-03-02
- Completion
- 2019-03-02
- First posted
- 2017-10-26
- Last updated
- 2023-03-13
Locations
1 site across 1 country: Argentina
Source: ClinicalTrials.gov record NCT03321695. Inclusion in this directory is not an endorsement.